Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets give up early gains
Thu, 6 Jan 11:30 am

After starting today's session on a positive note, Indian markets have lost ground and are trading in the red currently. Currently, heavyweights from the Sensex are trading weak with stocks from FMCG and auto space witnessing selling pressure. However, stocks from the IT and consumer durables space are trading with marginal gains.

Currently, the BSE-Sensex is trading down by around 60 points, while the NSE-Nifty is down by about 20 points. Selling pressure is also seen among the mid and small cap stocks, with the BSE-Midcap and BSE-Smallcap indices trading lower by 0.4% and 0.2% respectively.

Engineering stocks are trading mixed with TRF and Atlas Copco leading the gains. However, Punj Llyod and L&T are trading weak. Engineering major BHEL is considering a possibility to float a non-banking finance company (NBFC) to finance power projects. It has already appointed a consulting company to study the business model. Although at present, the planned NBFC will focus predominantly on power projects, the company is also keen on providing funding into other areas like equipment financing. It may be noted that right now there are only two niche power finance institutions in India - PFC and REC. Thus setting up a new financial arm will provide enough opportunities to BHEL.

Pharma stopcks are trading weak with Cipla and Dishman Pharma leading the pack of losers. However, Sun Pharma and Glenmark Pharma are trading flat. Dr. Reddy's has entered into a research partnership with UK based contract research organization Argenta. Argenta will use its drug discovery platform and expertise to find out potential new drug targets for Dr. Reddy's in the area of pain and inflammation. The financial implications of the deal are not available as yet. However, it may be noted that four years ago Dr. Reddy's had entered into a similar agreement with Argenta in the area of respiratory treatment and that research tie up has been progressing well.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets give up early gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.